Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.
Kwatra SG, Lio P, Weidinger S, Calimlim B, Ladizinski B, Vigna N, Botha W, Mansfield C. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Trea. 2023 Dec 1;34(1):2222201. doi: 10.1080/09546634.2023.2222201
Sola-Munoz S, Jorge M, Jimenez-Fabrega X, Jimenez-Delgado S, Azeli Y, Marsal JR, Jordan S, Mauri J, Jacob J. Prehospital stratification and prioritisation of non-ST-segment elevation acute coronary syndrome patients (NSTEACS): the MARIACHI scale. Intern Emerg Med. 2023 Aug 2;18(5):1317-27. doi: 10.1007/s11739-023-03274-z
Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382
Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski M, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Trea. 2021 Oct 6;1-9. doi: 10.1080/09546634.2021.1940810
Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J Dermatolog Trea. 2021 Feb 3;1-10. doi: 10.1080/09546634.2020.1839007
Martin SA, Brown TM, Fehnel S, Deal LS, Katz EG, Chiou CF. The atopic dermatitis itch scale: development of a new measure to assess pruritus in patients with atopic dermatitis. J Dermatolog Trea. 2020 Aug;31(5):484-30708. doi: 10.1080/09546634.2020.1713971
Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700
Giner-Soriano M, Teixido C, Marsal JR, Diez O, Pera H, Vlacho B, Morros R, working group for the clinical trial IJG-KOH-2014. Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children. J Dermatolog Trea. 2019 Dec;30(8):750-6. doi: 10.1080/09546634.2019.1573305
Montserrat-Capdevila J, Seminario MA, Godoy P, Marsal JR, Ortega M, Pujol J, Castan MT, Alseda M, Betriu A, Lecube A, Portero M, Purroy F, Valdivielso JM, Barbe F. Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors. Med Clin (Barc). 2018 Nov 21;151(10):383-9. doi: 10.1016/j.medcli.2017.12.018
Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464
Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.
Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Trea. 2016 Jan;27(1):19-26. doi: 10.3109/09546634.2015.1044492
Rebordosa C, Aguilera C. Safety of antiepileptic drugs during pregnancy. Med Clin (Barc). 2004 May 8;122(17):675-6.
Vallano A, Fortuny J, Arnau JM, Laporte JR. Generic drug prescription at discharge from a hospital emergency service. Med Clin (Barc). 2003 Nov 15;121(17):645-9. doi: 10.1016/s0025-7753(03)74048-2
Fortuny J, Agusti A. Secondary prevention of acute myocardial infarction: should oral anticoagulants and platelet antiaggregants be administered on a combined basis? Med Clin (Barc). 2003 Oct 4;121(11):433-5. doi: 10.1016 / S0025-7753 (03) 73977-3
Ascaso C, Garcia-Esteve L, Navarro P, Aguado J, Ojuel J, Tarragona MJ. Prevalencia de la depresión postparto en las madres españolas: comparación de la estimación mediante la entrevista clínica estructurada y la escala de depresión postparto de Edimburgo. Med Clin (Barc). 2003 Mar 15;120(9):326-9. doi: 10.1157 / 13044232
Pladevall-Vila M, Gabriel R, Yanez A, Sanchez LM, Sobrino J, Marquez E. Therapeutic compliance interventions: a clinical trial. Med Clin (Barc). 2001;116(Suppl 2):63-7.
Arana A, Piero P. Validity of a quick method to identify e. coli and proteae in urine samples. Med Clin (Barc). 1994 Jan;693. doi: 10.1016/j.ahj.2013.12.006
Rivero E, Carrillo E, Portella E, Hernández I, Colom D. Evaluation of the design and reliability of a questionnaire to identify elderly individuals in need for social and health services. Med Clin (Barc). 1993 Dec;101(18):688-92.
Brotons C, Rué M, Rivero E, Pérez G. Tendencies of mortality from cardiovascular diseases in Catalonia: 1975-1992. Med Clin (Barc). 1993 Nov 13;101(16):604-8.
Walker AM, Garcia Rodriguez LA, Perez GS. Epidemiology and the pharmaceutical industry [La epidemiología y la industria farmacéutica]. Med Clin (Barc). 1992 Mar 28;98(12):465-8.